Neuroleptic malignant syndrome and serotonin syndrome

Laura M. Tormoehlen, Daniel Rusyniak

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


The clinical manifestation of drug-induced abnormalities in thermoregulation occurs across a variety of drug mechanisms. The aim of this chapter is to review two of the most common drug-induced hyperthermic states, serotonin syndrome and neuroleptic malignant syndrome. Clinical features, pathophysiology, and treatment strategies will be discussed, in addition to differentiating between these two syndromes and differentiating them from other hyperthermic or febrile syndromes. Our goal is to both review the current literature and to provide a practical guide to identification and treatment of these potentially life-threatening illnesses. The diagnostic and treatment recommendations made by us, and by other authors, are likely to change with a better understanding of the pathophysiology of these syndromes.

Original languageEnglish (US)
Title of host publicationHandbook of Clinical Neurology
PublisherElsevier B.V.
Number of pages13
StatePublished - Jan 1 2018

Publication series

NameHandbook of Clinical Neurology
ISSN (Print)0072-9752
ISSN (Electronic)2212-4152


  • bromocriptine
  • cyproheptadine
  • dantrolene
  • hyperthermia
  • malignant catatonia
  • neuroleptic malignant syndrome
  • serotonin syndrome

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Neuroleptic malignant syndrome and serotonin syndrome'. Together they form a unique fingerprint.

  • Cite this

    Tormoehlen, L. M., & Rusyniak, D. (2018). Neuroleptic malignant syndrome and serotonin syndrome. In Handbook of Clinical Neurology (pp. 663-675). (Handbook of Clinical Neurology; Vol. 157). Elsevier B.V..